Q-omics provides the consensus-scored MIOX profile across patient tissues and cancer cell-line models. MIOX expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIOX is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, MIOX RNA expression shows 14,299 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRP, and UVM as cancer lineages where MIOX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIOX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIOX survival associations across molecular data types. MIOX RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIOX RNA expression–survival associations across cancer types. High MIOX expression shows unfavorable associations in ACC, MESO, UVM and LGG, but favorable associations in KIRC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIOX RNA expression.
This table summarizes MIOX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MIOX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIOX shows lower tumor expression in KIRP, THCA and KICH and higher tumor expression in COAD, HNSC and LUAD. The KIRP box plot shows higher MIOX RNA expression in normal versus tumor tissue (log2 FC = −4.996, t-test p < 0.001).
This table shows molecular features associated with MIOX in patient tissues and cancer cell lines. In patient samples, MIOX shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIOX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
